About Fabhalta® (iptacopan) Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway 6-7.

The molecular glue space has attracted several Big Pharma players over the past few years, including Novo Nordisk, Pfizer and ...

"Living with kidney disease is a difficult challenge to navigate for patients and their families, and it can feel even more isolating and frustrating when you are living with a rare kidney disease,” ...

Novartis (NVS) announced that the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has adopted a ...

For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. | For GSK CEO Emma Walmsley, ...

Researchers conduct a retrospective, population-based cohort study of adult patients with metastatic breast cancer who underwent genomic profiling at academic institutions.

Sigma Planning Corp cut its holdings in Novartis AG (NYSE:NVS – Free Report) by 19.3% during the 4th quarter, HoldingsChannel.com reports. The fund owned 4,218 shares of the company’s stock after ...

Novartis' dividend yield currently stands at 3.58%, which is significantly higher than that of the healthcare sector. Read ...

Emasan AG, the investment arm of the Sandoz family, has sold a significant stake in Swiss pharmaceutical giant Novartis ...

A federal court rejected Novartis' legal challenge to the Medicare Drug Price Negotiation Program, ruling that it does not ...

Syngenta, which has a major operational base in Greensboro, said Wednesday it has signed an agreement to acquire certain product rights from Novartis, along with the recent opening of its ...

The transaction includes the Novartis repository of natural compounds and genetic strains for agricultural use.